News by topic

Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Generic medicines news

Show

From To
Pharmaceutical industry
Mylan to Provide Generic Truvada for U.K. Trial

The NHS confirmed Thursday that Mylan had won the drug procurement process for a three-year-long implementation trial for pre-exposure prophylaxis, or PrEP, which is used to prevent HIV infection.

Published
03 August 2017
From
Wall Street Journal
Access to medicines and treatment
Countries and donors should aim for new $90-$90-$90 target on HIV, hepatitis, TB drug prices, study shows

HIV, hepatitis B and C and tuberculosis (TB) can each be treated for less than $90 a year where generic drugs can be made available, Dzintars Gotham

Published
27 July 2017
By
Keith Alcorn
New and experimental hepatitis C treatment
WHO prequalifies first generic hepatitis C medicine and first HIV self-test

WHO today prequalified the first generic version of sofosbuvir, a critical medicine for the treatment of hepatitis C. The development could expand access to treatment by increasing the number of quality-assured generic medicines on the market. Sofosbuvir, 400 mg tablet, is manufactured by Mylan Laboratories Ltd., India.

Published
22 July 2017
From
World Health Organization
Generic medicines
Surprise FDA Approval of Generic Truvada Is a 'Wakeup Call' for Activists

The surprise approval of generic Truvada (tenofovir disoproxil fumarate and emtricitabine) by the U.S. Food and Drug Administration (FDA) on June 9 left patients, advocates and doctors scrambling to understand exactly when the generic will become available and how much it will cost.

Published
07 July 2017
From
The Body
PrEP
Generic PrEP approved, but not soon available

The U.S. Food and Drug Administration has approved the first generic version of Truvada, a combination pill used for both HIV treatment and prevention, but it will not soon hit pharmacy shelves, advocates said.

Published
17 June 2017
From
Bay Area Reporter
PrEP policies and guidelines
FDA Approves Generic Truvada for HIV Treatment and PrEP

In a move that has taken HIV advocates by surprise and stewed considerable confusion, the U.S. Food and Drug Administration (FDA) has approved a generic formulation of Gilead Sciences’ blockbuster antiretroviral (ARV) Truvada (tenofovir disoproxil fumarate/emtricitabine). This decision could have major implications for the future cost of Truvada, to insurers and consumers alike.

Published
10 June 2017
From
Poz
Generic medicines
Unexpected side effects with generic abacavir – and potential for rare reactions to other generic ARVs

Several anecdotal reports of mouth ulcers have recently been reported in people switching to generic abacavir in the UK. This should highlight awareness of the potential of likely-rare new side effects, even when both formulations have been approved as bioequivalent.

Published
23 May 2017
From
HIV i-Base
Pharmaceutical industry
CHMP recommends for approval generic version of Atripla

At its May meeting, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended for approval a generic version of Atripla – Efavirenz/Emtricitabine/Tenofovir disoproxil Zentiva (efavirenz/emtricitabine/tenofovir disoproxil) for the treatment of HIV infection.

Published
22 May 2017
From
EATG
Generic medicines
Switching from Atripla to generic-containing regimens can produce large cost savings

Switching from branded Atripla to regimens that include at least one generic drug formulation can achieve big cost savings without compromising virological efficacy, according to research from Brighton presented

Published
23 April 2017
By
Michael Carter
Hepatitis C treatment
Malaysia: MOH to propose importing generic Hepatitis C meds

The Health Ministry will table a working paper to the Cabinet committee for approval to import of generic drugs to treat Hepatitis C.

Published
14 March 2017
From
Malay Mail Online
← Prev1...23456Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.